PFIZER INC·4

Apr 27, 6:22 PM ET

Taraporevala Cyrus 4

Research Summary

AI-generated summary

Updated

Pfizer Director Cyrus Taraporevala Receives Award of 7,686 Phantom Shares

What Happened Cyrus Taraporevala, a director of Pfizer Inc. (PFE), received an award of 7,686.539 derivative units (phantom shares) on 2026-04-23. The units are valued at $26.67 each, for a total grant value of $205,000. The transaction is reported as an Award/Grant (code A) under Pfizer’s non‑employee director deferred compensation plan.

Key Details

  • Transaction date: 2026-04-23; Filing date (Form 4): 2026-04-27 (timely — within two business days).
  • Award: 7,686.539 units at $26.67 per unit; total value $205,000 (derivative).
  • Transaction code: A (Grant/Award).
  • Plan: Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non‑Employee Directors (per filing).
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes: F1 — each unit = one phantom share; F2 — granted under the non‑employee director plan; F3 — units represent deferred director compensation settled in cash or common stock at the director’s election upon retirement.

Context These are deferred compensation units (phantom shares), not an open‑market purchase or immediate stock issuance. They typically reflect routine director compensation and will be paid in cash or converted to stock at the director’s election following retirement, so they do not by themselves indicate an immediate bullish or bearish trading signal.